Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05845567
Other study ID # ITF/2357/55 - PART 2
Secondary ID 2021-005756-11
Status Completed
Phase Phase 1
First received
Last updated
Start date March 21, 2022
Est. completion date May 24, 2022

Study information

Verified date May 2023
Source Italfarmaco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of Givinostat plus Clarithromycin.


Description:

This study was planned as a phase I, open-label, 3-part, fixed-sequence, non-randomized study in healthy male and female subjects. The study (Part 2) aimed at assessing the potential effect of Clarythromycin on the single dose pharmacokynetics of Givinostat. The total duration of Part 2 was divided as follows: - Screening: up to 21 days. - Treatment Period: Days 1 to 11. - Safety follow-up visit: 12±2 days. Subjects were confined at site from Day -1 to Day 11. On Days 1 and 8, a single dose of 50 mg Givinostat, as oral suspension, was administered 1 hour after the planned morning time of Clarithromycin administration. From Day 4 to Day 10, clarithromycin 500 mg film-coated tablets were administered twice a day, in the morning and in the evening. The following assessments were performed: - Blood collection for pharmacokinetic analysis on Days 1 to 4 and 8 to 11. - Vital signs measurements on Days 1 and 4 to 10. - 12-lead ECG on Days 1, 3, 7 and 8. - Blood collection for laboratory tests (hematology and biochemistry) on Day 3. Subjects were discharged in the morning of Day 11 after completing end of study procedures.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 24, 2022
Est. primary completion date May 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - A subject was considered eligible for the study if he/she fulfilled all the inclusion criteria: 1. Subject's written informed consent obtained prior to any study-related procedure. 2. Male or female subject, =18 and =55 years of age, at the time of signing the informed consent. 3. Body mass index (BMI) of 18.5 to 32.0 kg/m2 inclusive, and body weight =55 kg and =100 kg for females and body weight =60 kg and =110 kg for males. 4. Non-smoker or ex-smoker (i.e. someone who abstained from using tobacco or nicotine-containing products for at least 3 months prior to Screening). 5. No clinically relevant diseases. 6. No major surgery within 4 weeks prior to dosing. 7. No clinically relevant abnormalities on physical examination. 8. No clinically relevant abnormalities on 12-lead ECG. 9. No clinically relevant abnormalities on clinical laboratory tests. 10. Negative test results for anti-Human Immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), Hepatitis B surface antigen (HBsAg) and anti-Hepatitis C virus antibodies (anti-HCVAb). 11. Female subjects are eligible if they are of non-childbearing potential or agree to use a non-hormonal highly effective contraceptive method from 28 days prior to Screening until at least 90 days after the last study drug administration. Nonchildbearing potential female is defined as: 1. Menopausal, i.e. no menses for = 12 months without an alternative medical cause other than menopause, and a high FSH level. 2. Pre-menopausal female with documented hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy. A non-hormonal effective contraceptive method is defined as: 1. Intrauterine device. 2. Bilateral tubal occlusion. 3. Total abstinence of heterosexual intercourse, in accordance with the lifestyle of the subject. 4. Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner. 12. Male subjects who are sexually active with a female partner of childbearing potential (pregnant or non-pregnant) must use contraception (condom) from investigational product administration up to at least 90 days following the last study drug administration. 13. Male subjects must ensure that his non-pregnant female partner of childbearing potential agrees to consistently and correctly use for the same period a highly effective method of contraception (see Section 8.5.3). 14. Male subjects must be willing not to donate sperm until 90 days following the last study drug administration. 15. Willingness and capability to comply with the requirements of the study and ability to understand the study procedures and the risks involved. Exclusion Criteria - A subject was excluded from the study if he/she fulfilled any of the exclusion criteria: At Screening 1. Previous use of Givinostat. 2. History of anaphylaxis reaction or clinically significant drug hypersensitivity reaction (e.g., angioedema, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, drug-induced hypersensitivity syndrome, druginduced neutropenia). 3. Known history of hypersensitivity and/or allergic reactions to Givinostat, histone deacetylases (HDAC) inhibitors or to any excipient in the formulation. 4. History of sorbitol intolerance, sorbitol malabsorption or fructose intolerance. 5. Any medical condition (e.g. gastrointestinal, renal or hepatic, including peptic ulcer, inflammatory bowel disease or pancreatitis) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion) or subject safety. 6. Systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 60 or over 90 mmHg, or pulse rate lower than 50 or over 100 bpm. 7. QTcF ?450 msec. 8. Subjects with history of cardiac arrhythmias (documented), family history of sudden cardiac death or history of additional risk factors for torsades-depointes (e.g. heart failure, hypokalemia, long QT syndrome). 9. Having an estimated glomerular filtration (eGFR) < 90 mL/min, based on creatinine clearance calculation by the Cockcroft-Gault formula and normalized to an average surface area of 1.73 m2. 10. Any of the following abnormal laboratory test values: 1. Platelet count below the lower limit of the normal range (LLN). 2. Total white blood cells count below the LLN. 3. Hemoglobin below the LLN. 4. Triglycerides above the upper limit of normal range (ULN). 5. Potassium or magnesium below the LLN. 11. Positive urine alcohol, drugs-of-abuse or cotinine screen tests. 12. Positive serum pregnancy test. 13. If woman, she is breast-feeding. 14. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (i.e. more than 14 units of alcohol per week for males or more than 7 units for females). 15. History of drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs [such as cocaine, phencyclidine (PCP), crack, opioid derivatives including heroin, and amphetamine derivatives] within 1 year prior to screening. 16. Participation in any clinical trial within the previous 2 months. 17. Participation in more than 2 clinical trials within the previous 12 months. 18. Blood donation or significant blood loss (= 450 mL) due to any reason or had plasmapheresis within the previous 2 months. 19. Veins unsuitable for intravenous puncture on either arm. 20. Difficulty in swallowing capsules, tablets or suspensions. 21. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study. 22. Known history of hypersensitivity and/or allergic reactions to clarithromycin, other macrolides or to any excipient in the formulation. At Admission to Treatment Period 23. Any clinically relevant abnormalities on clinical laboratory tests. 24. Positive urine alcohol, drugs-of-abuse or cotinine screen tests. 25. Positive urine pregnancy test. 26. Positive or inconclusive SARS-CoV-2 test prior to admission. 27. Use of prescription or non-prescription medicinal products within the previous 28 days or within 5-half-lives of the medicinal product, whichever is longer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Givinostat
ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
Clarithromycin
Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.

Locations

Country Name City State
Portugal Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires Porto

Sponsors (1)

Lead Sponsor Collaborator
Italfarmaco

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax of Givinostat, Following Single Doses of the Parent Drug Maximum observed plasma concentration (Cmax) of givinostat.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.
In the turn of 72 hours after administration of Givinostat
Primary AUC0-t of Givinostat, Following Single Doses of the Parent Drug AUC0-t = area under the curve from time zero to last sampling time with quantifiable concentrations.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of Givinostat, on Days 1 and 8, for the determination of Givinostat.
In the turn of 72 hours after administration of Givinostat
Primary AUC0-inf of Givinostat, Following Single Doses of the Parent Drug AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/?z, where Clast is the last measurable concentration and ?z is the apparent terminal elimination rate constant.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat.
In the turn of 72 hours after administration of Givinostat
Primary %AUCextrap of Givinostat, Following Single Doses of the Parent Drug %AUC0extrap = Percentage of AUC0-8 due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ·(AUC0-8 - AUC0-t) / AUC0-8.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat
In the turn of 72 hours after administration of Givinostat
Primary Tmax of Givinostat, Following Single Doses of the Parent Drug Tmax =The time of occurrence of maximum observed concentration of Givinostat.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.
In the turn of 72 hours after administration of Givinostat
Primary ?z of Givinostat, Following Single Doses of the Parent Drug ?z is the apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non- zero concentrations.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of givinostat
In the turn of 72 hours after administration of Givinostat
Primary t1/2 of Givinostat, Following Single Doses of the Parent Drug t1/2 is the apparent terminal elimination half-life, calculated as ln(2)/?z.
A total of 40 blood samples were collected as follows:
- Twenty (20) blood samples at pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60 and 72 hours after the administration of givinostat, on Days 1 and 8, for the determination of Givinostat.
In the turn of 72 hours after administration of Givinostat
Secondary Severity of Treatment Emergent Adverse Events (TEAE) An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit. Throughout the study and 10-14 days after the EoS (follow-up visit), i.e. up to day 30-34
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1